RU / EN

Kit for determination of the resistance of tuberculosis mycobacteria to rifampicin and isoniazid has been registered

The TestGene company has registered the kit "MTB-RESIST-I-test" for qualitative determination of the status of rpoB, katG and inhA gene polymorphisms associated with drug resistance to first-line chemotherapy drugs – rifampicin and isoniazid – and their analogues.

Isoniazid and rifampicin are one of the main drugs for treatment of tuberculosis. But, according to experts, the proportion of patients with multidrug-resistant tuberculosis (MDR-TB) is growing; this is tuberculosis in which the pathogens of the disease are resistant to at least isoniazid and/or rifampicin.

Today, almost every fifth newly diagnosed patient has resistance to the main strongest drugs and there are about 40% of such patients among patients who have previously been treated.

"Patients multidrug-resistant tuberculosis can be successfully treated with back-up antibiotics, new protocols and integrated treatment approaches. But in order to choose the appropriate therapy, it is necessary to quickly understand whether pathogens are resistant to certain drugs or not, says Alexei Solovyov, PhD in Biology, Head of the PCR development department at TestGene. – To determine the drug resistance of MBT by traditional microbiological methods, an average of 8-12 weeks is required. The kit "MTB-RESIST-I-test" developed by us makes it possible to detect mutations in the rpoB, katG and inhA genes and, accordingly, MTB drug resistance to rifampicin and isoniazid and their analogues accurately (kit has 100% sensitivity and specificity) and fast (within 125-165 minutes)".

The possibility to use almost any available material for the analysis, including blood and urine, the use of only three tubes per patient, as well as the compatibility of the test system with all open-type cyclers with five detection channels makes the kit "MTB-RESIST-I-test" one of the most convenient, easy-to-use and versatile products for determination of antibiotic resistance of tuberculosis mycobacteria.


All news